File(s) not publicly available

Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life

journal contribution
posted on 2018-11-01, 00:00 authored by Donald D Chang, Harris A Eyreeuro, Ryan Abbott, Michael Coudreaut, Bernhard T Baune, Jeffrey A Shaman, Helen Lavretsky, Eric J Lenze, David A Merrill, Ajeet SinghAjeet Singh, Benoit H Mulsant, Charles F Reynolds, Daniel J Müller, Chad Bousman
Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.

History

Journal

Pharmacogenomics

Volume

19

Issue

16

Pagination

1269 - 1284

Publisher

Future Medicine

Location

London, Eng.

eISSN

1744-8042

Language

eng

Publication classification

C1 Refereed article in a scholarly journal